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Abstract
Background—The challenge of angiogenesis science is that stable sustained vascular regeneration
in humans has not been realized despite promising preclinical findings. We hypothesized that
angiogenic therapies powerfully self-regulate by dynamically altering tissue characteristics. Induced
neocapillaries increase drug clearance and limit tissue retention and subsequent angiogenesis even
in the face of sustained delivery.
Methods and Results—We quantified how capillary flow clears Fibroblast Growth Factor (FGF)
following local epicardial delivery. FGF spatial loading was significantly reduced with intact
coronary perfusion. Penetration and retention decreased with trans-endothelial permeability, a trend
diametrically opposite to intravascular delivery, where factor delivery depends on vascular leak, but
consistent with a continuum model of drug transport in perfused tissues. Model predictions of FGF
sensitivity to manipulations of its diffusivity and trans-endothelial permeability were validated by
conjugation to sucrose octasulfate (SOS). Induction of neocapillaries adds pharmacokinetic
complexity. Sustained local FGF delivery in vivo produced a burst of neovascularization in ischemic
myocardium but was followed by drug washout and a five-fold decrease in FGF penetration depth
Conclusions—The very efficacy of pro-angiogenic compounds enhances their clearance and
abrogates their pharmacologic benefit. This self-limiting property of angiogenesis may explain the
failures of promising pro-angiogenic therapies.
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Introduction
Stimulation of neovascularization using angiogenic growth factors might reduce myocardial
infarct size and improve cardiac function1, and peripheral tissue2 perfusion. Yet, impressive
results in tissue culture and animal studies3–7 have not been sustained in clinical trials8–11.
Intravascular delivery of angiogenic factors is convenient but challenged by the requirements
for high doses and long residence times8, 10. Cell and gene injections might provide a
continuous source of growth factor, and intramyocardial or pericardial delivery have elevated
local tissue drug concentrations with lower systemic exposure in animal models12. However,
the promise of symptomatic improvement and increased capillary density seen in early clinical
trials with intramyocardial injections of FGF after coronary artery bypass grafting13 has not
endured in larger clinical trials, and clinical outcomes in general with local growth factor
delivery have been mixed9, 14–18.
Some have postulated that myocardial growth factor concentrations and/or drug residence time
were inadequate for sustained angiogenesis despite controlled release delivery19. However,
the local pharmacokinetic processes governing uptake and distribution of growth factors in
highly vascularized tissues such as myocardium remain ill-defined. It is therefore possible that
the reverse is true and that growth factor concentrations were actually more than sufficient
initially. We hypothesized that local delivery can induce neocapillary growth but in doing so
changes the balance between drug delivery and microvascular drug clearance to favor the latter,
such that the very pharmacologic efficacy of these compounds limits their biological effect.
We used a series of ex vivo, analytical and in vivo experimental animal models to quantify how
growth factors distribute within vascularized tissue, and how neovascularization following
delivery of angiogenic growth factors affects their pharmacokinetics and efficacy. These
studies strongly suggest that angiogenesis is powerfully self-regulating as the capillaries
induced by angiogenic drug therapy may increase clearance rates limiting tissue levels of
growth factor and subsequent angiogenesis even with sustained delivery.
Methods
Ex-vivo Myocardial Drug Delivery with and without Perfusion
Sprague Dawley rats (0.5–0.6 kg) were anesthetized with 35 mg/kg ketamine and 5 mg/kg
xylazine, and anticoagulated with 1000 U subcutaneous heparin prior to CO2 euthanasia . The
aorta was cannulated and heart retrograde perfused with cardioplegia (Osmolality = 289 mOsm/
kgH2O ± 5%) composed of Krebs-Henseleit buffer (Sigma-Aldrich) with high potassium (30
mmol/L KCl) and 4 % BSA (Sigma-Aldrich) to establish diastolic arrest. The heart was excised
and perfused at 95 mmHg. Coronary flow was monitored periodically and ranged 8–10 ml/
minutes throughout experiment. The perfusate was oxygenated by a foam bubble oxygenator
with 95 % O2 / 5 % CO2 at 37°C. Samples were also examined in the absence of coronary
perfusion to eliminate other effects. Here the aorta was cannulated and flushed with perfusate.
As blood cleared from the circulation, coronary outflow from coronary sinus was stopped by
clamping the right atrium and pulmonary artery ensuring myocardial capillaries patency and
that the only difference between the control and perfused cases was coronary perfusion. The
entire configuration resided within an enclosed box with 100 % humidity. We ascertained
myocardial viability at 6 h by quantitatively documenting no additional tissue edema on H&E
stained sections. Experimental protocols were in accordance with NIH guidelines for the
humane care and use of laboratory animals and MIT committee on animal care.
Texas Red-FGF2 (TR-FGF2, 17 kDa, 5.88×10−2 μmol/L) or Texas Red labeled FGF2
conjugated to SOS complex (TR-(FGF2)2-SOS complex, ~35 kDa, 2.86×10−2 μmol/L) were
delivered to the rat myocardium from a drug-releasing chamber affixed to the anterior
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epicardial surface by a cyanoacrylate based surgical adhesive (Glustitch). Heart were placed
on a shaker at 100 RPM to ensure a well mixed epicardial drug source. A core of myocardial
tissue in contact with and immediately adjacent to the drug source was harvested 6 h later using
an 8 mm-diameter biopsy punch (Miltex). Tissue cores were cryo-sectioned (Leica CM1850)
perpendicular to the epicardium for quantitative epifluorescence imaging (Leica DMRA2
microscope, Hamamatsu C4742-95 camera, MetaMorph software, Texas Red filter set). Since
the fluorescent intensity of TR-FGF2 is linearly proportional to fluorophore20, total drug
deposition in the absence (M diff) or the presence (M diff-clear) of coronary perfusion were
calculated by summing fluorescence intensities in the spatial distributions. Percent clearance
of drug from coronary perfusion is
(Eq. M1)
In-vivo Myocardial Drug Delivery
Rabbits (New Zealand White, 3–3.5 kg) received an intramuscular injection of 35 mg kg−1
ketamine and 5 mg kg−1 of xylazine, and inhaled isoflurane anesthesia (1–3%) and positive
pressure ventilation via a 3.0 mm endotracheal tube. The chest was shaved and sterilely
prepared with Betadine and alcohol. A left thoracotomy was performed after local lidocaine
injection. A clamp kept the chest open and a small opening in the pericardium was created with
care to minimize pericardial damage. The left anterior descending coronary artery was ligated.
Ischemia was confirmed by ST segment elevation on simultaneous continuous
electrocardiography. Sodium alginate polymeric devices sustain-releasing 35S-FGF1 from
encapsulated heparin Sepharose beads (Supplemental Materials) were placed in the pericardial
space and the percardiotomy suture repaired to prevent leakage. The thoracotomy and skin
incision were closed. Positive end-expiratory pressure ventilation and a negative pressure chest
tube prevented pneumothorax. Analgesia was with 0.03 mg kg−1 buprenorphine subcutaneous
injections every 8 h for the first 72 h. Control animals received alginate encapsulated heparin
Sepharose beads without FGF. Hearts were harvested 2, 8, 16 and 31 days after surgery, the
aorta cannulated, flushed retrogradely with PBS, and snap-frozen in liquid nitrogen.
Quantification of in-vivo FGF1 and Blood Vessels Distribution
Two frozen myocardial cores were excised adjacent to the polymeric devices using an 8 mm
diameter biopsy punch (Miltex). One core was mounted and cryosectioned (Leica CM1850)
into 100 μm sections parallel to the epicardium. Sections were digested in 1 ml of Solvable
tissue solubilizer (PerkinElmer) at 60°C overnight prior to radioactivity quantification
(2500TR Liquid Scintillation Analyzer, Packard). The discrete spatial FGF1 concentration data
were fit to the exponential profile implied by Eq. 4 (Table 1) using GraphPad software (Prism
5). The fit was used to estimate the penetration depth x90, defined as distance from source to
90 % drop-off threshold, as x90 = ℓ × ln(10). The other tissue core was cryo-sectioned into 10
μm thick sections in transmural direction. Sections were fixed for 5 m with 4 %
paraformaldehyde (Electron Microscopy Sciences), washed for 30 s with cold acetone (Sigma-
Aldrich), incubated in blocking serum (200 μl 1 % chicken serum, 1 h, 37°C), then in goat anti-
PECAM-1 IgG (Santa Cruz Biotechnology, 200 μl of 1:50 dilution, 2 h, 37°C), washed three
times in 0.1 % Tween 20 in PBS, incubated further with Alexa Fluor 488 chicken anti-goat
IgG (Invitrogen, 200 μl 1:200 dilution, 2 h, 37°C), washed three times in Tween 20/PBS, cover-
slip mounted, and imaged immediately with a fluorescence microscope (Leica DMRA2, FITC
filter set). The images were thresholded to maximize the signal to noise ratio with Matlab
(Mathworks, MA), yielding binary images of vessel distribution. Neovascular formation of
tissue regions within 500 μm from epicardial source was quantified by computing the tissue
area fraction stained by PECAM-1 (total number of pixels with PECAM-1 stain / total number
of pixels of tissue area).
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Statistical analysis
All data were presented as means ± s.e.m., except values for the clearance rate constants k
which were reported as means ± propagated standard errors. Propagated errors sk were
calculated using the formula , where sD and  are standard errors for
effective diffusivity D and penetration depth x90, respectively. Statistical analyses were
performed with the Student's t test where appropriate. P<0.05 (two-tailed) was considered
statistically significant. Non-linear regression was performed using GraphPad software (Prism
5) to fit steady state spatial drug distributions to Eqs. S6 and S11 in obtaining values for
clearance rate constant k and effective diffusivity D, respectively.
Results
FGF Distribution is Limited by Myocardial Perfusion
Drug transport through and deposition within tissues are governed by molecular weight-
dependent processes such as diffusion and convection, and physicochemical attributes such as
binding, partitioning, and metabolism21–23. We examined the effects of capillary perfusion on
myocardial growth factor transport in rat hearts incubated at constant epicardial source
concentrations (Fig. S1) with and without controlled coronary flow. When delivered to the ex-
vivo myocardium in the absence of flow, TR-FGF2 distributed via diffusion to a penetration
depth of 66 μm in 6 h (Fig 1). Restoration of coronary perfusion reduced TR-FGF2 penetration
depth more than 2-fold to 28 μm, localizing growth factor closer to the epicardial drug source
(Fig. 2).
Drug Diffusivity, Trans-endothelial Permeability and Vessel Density Influence Local Drug
Distribution and Deposition
We examined the impact of coronary flow on drug penetration within the context of a
continuum pharmacokinetics model of drug diffusion in the face of microvascular clearance
(Eq. 1, Table 1). In the absence of perfusion the growth factor distribution curve mimics the
analytical solution of the diffusion equation (Eq. 3, Table 1) with an apparent diffusivity of
0.021 ± 0.001 μm2s−1 for TR-FGF2. This value is four orders of magnitude smaller than the
reported diffusivity of FGF in free aqueous solution24, reflecting the impact of steric hindrance
and binding within tissues. TR is small (600 Da) and hydrophilic. Its diffusion is significantly
higher than FGF in HSPG-rich myocardium and detected fluorescence is likely specific for
TR-FGF-2. In the presence of coronary perfusion, the capacity of capillaries to clear drugs is
restored and the distribution of TR-FGF2 at 6 h approaches an exponential steady state profile
consistent with an apparent clearance rate constant k = 1.15 ± 0.06×10−4 s−1 (Eq. 4, Table 1).
Given a normal myocardial capillary density of ~ 12.9 %25 and FGF2 aqueous diffusivity of
2.2×102 μm2s−1 24, our estimate of the clearance rate constant of FGF2 implies that trans-
endothelial permeability and the permeability-to-diffusivity ratio are approximately
1.9×10−3 μms−1, and 8.8×10−6 μm−1. This estimate is in line with the trans-endothelial
permeability of a molecule with a molecular size of FGF226.
Analytic models of drug transport and loss to capillary flow were evaluated across a range of
diffusivities, trans-endothelial permeabilities, and microvascular volume fractions. Steady
state results (Eqs. S7 and S9, Supplemental Methods) were used as equilibrium is rapidly
achieved. Penetration depth at steady state increases as the square root of the diffusion
coefficient (Fig. 2a), and decreases as the square root of the trans-endothelial permeability
constant (Fig. 2b). It is worth contrasting our results with those from systemic drug delivery
through an intravascular route, where tissue absorption is proportional to trans-endothelial
permeability. Increasing transvascular penetration in systemic delivery requires drugs that
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permeate across the endothelium and interventions that increase, rather than decrease, vascular
permeability27–29. Tissues with higher degrees of vascularization, as embodied by the vascular
volume fraction, clear drugs faster and have lower steady state drug penetration (Fig. 2c). Thus,
steady state drug penetration and distribution are highly dependent on drug diffusivity through
tissue and net microvascular clearance, the compounded effect of trans-endothelial
permeability and microvascular volume fraction (Eq. 2, Table 1).
The theoretical reduction in total deposition due to capillary clearance was calculated (Eq. 5,
Table 1) and expressed as a function of the clearance rate constant k (Eqs. S8 and S12,
Supplemental Methods). Percent clearance of drug with coronary perfusion is most sensitive
for clearance rate constants ranging between 1×10−5 and 1×10−2 s−1 (Fig. 3a). Notably, our
measurement of the clearance rate constant of TR-FGF2 falls within this range, suggesting that
FGF clearance is highly sensitive to trans-endothelial permeability and microvascular volume
fraction.
To examine whether the clearance rate constant of FGF might be modulated by altering its
physicochemical properties, we used quantitative fluorescence imaging to contrast the
distribution of TR-FGF2 alone or in association with SOS. SOS induces FGF dimerization and
increases the effective molecular weight of TR-FGF230. The increase in size was confirmed
by size-exclusion chromatography, and should reduce trans-endothelial permeability, capillary
washout, and effective diffusivity. Indeed, in the absence of coronary perfusion, TR-
(FGF2)2-SOS penetrated 40 % less than TR-FGF2 into the myocardium (40 μm, with an
effective diffusivity of 0.013 ± 0.001 μm2s−1) reflecting its increased size (Deff TR-FGF = 0.021
± 0.001 μm2s−1, Fig. 1 vs. Fig. 3b). But the larger compound was also less affected by coronary
perfusion, with penetration depth falling only 26 % to 30 μm and total deposition falling by
only 12 % (Fig. 3b). The muted sensitivity of TR-(FGF2)2-SOS to flow is consistent with the
estimated clearance rate constant (k=4.37 ± 0.33×10−5 s−1), model predictions (Fig 3a), and
our hypothesis that larger molecules enter capillaries less readily.
In-vivo Angiogenic Response Limits Drug Distribution
Conventional pharmacokinetic models for drug distribution do not take into account the
potential that drugs can alter capillary density, trans-endothelial permeability or drug clearance.
Yet, angiogenic growth factors such as FGF1 and FGF2 are specifically administered to induce
capillary growth, and it would be unreasonable to assume that trans-endothelial permeability
and drug clearance are not similarly modified. Induced neovascularization implies an increase
in the density of blood capillaries that could provide negative feedback limiting growth factor
tissue penetration (Fig 2c). Our analysis of myocardial drug transport suggests that FGF would
be particularly sensitive to induced capillary washout (Figs. 1 and 3a). We tested this hypothesis
in vivo using radiolabeled FGF1 (35S-FGF1). TR-FGF2 could not be used in vivo as its labeling
intensity is much lower than that of 35S-FGF1, rendering it virtually transparent at the doses
delivered. Notably, ex-vivo experiments with 35S-FGF1 were well explained by the diffusion-
clearance model, and suggest that the transport parameters estimated for TR-FGF2 is similar
to those of 35S-FGF1 (Supplement).
Heparin-bound biologically active 35S-FGF1 fractions were isolated, incorporated into heparin
Sepharose-alginate wafers which sustain-release FGF1 for over 30 days in vitro and in vivo
(Fig. 4b), and implanted in the pericardial space of ischemic rabbit hearts (Fig. 4a). FGF1
successfully penetrated 442 ± 91 μm into the myocardium over the first two days after release
initiation. Yet, despite sustained delivery, penetration regressed over time falling 5-fold by day
8 (81 ± 30 μm), and remained low through day 31 (Fig. 5a). Enhanced growth factor clearance
was associated with the induction of neovasculature. Two days after device implantation the
fraction of PECAM-1 stained tissue was 56 % greater in animals receiving FGF1 (4.4 %)
compared to baseline density (2.8 %) in control animals with identical devices devoid of growth
Le et al. Page 5
Circulation. Author manuscript; available in PMC 2010 June 9.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
factor (P < 0.05, Fig. 5c). Neovascularization peaked at day 8 (8.7 %) doubled that from day
2 (P < 0.01, Fig. 5c), coinciding with the drop in drug distribution. Similarly, the fraction of
PECAM-1 stained tissue decreased significantly from day 8 to day 31 (−62 % P < 0.01, Fig.
5c), most likely from regression of neocapillaries as the concentration of FGF1 becomes sub-
therapeutic. Examination of drug delivery devices for remaining drug content confirmed that
the decreasing myocardial concentrations arose from increasing capillary clearance rather than
decreasing drug delivery. None of the delivery devices were depleted of drug, and all continued
to release drug with constant flux (Fig. 4b) following the expected burst release of ~37.5 %
during the first 6 h.
Discussion
The potential of angiogenic promoters of endothelial cell growth and neovascularization is
well established in cell and tissue culture 31, 32. Yet, angiogenic growth factors have yet to
produce stable sustained angiogenesis in clinical trials8, 10. While there are undoubtedly
biological factors involved33, our study suggests that fundamental transport barriers and
particularly the self-limiting pharmacokinetics of angiogenic therapy also may impair the
realization of sustained neovascularization.
Our results reveal that drug trans-endothelial permeability plays a vital role in governing drug
distribution. Lower trans-endothelial permeability ensures greater myocardial drug penetration
following local application (Fig. 2b). FGF is an arterial vasodilator but this cannot explain our
results as expected changes in arteriolar volume34 could not reach the scale of our results or
explain the difference in growth factor distribution between perfused and static flow conditions
which both saw growth factor. The dependence of drug distribution on trans-endothelial
permeability and capillary density takes on further complexity for angiogenic compounds that
can remodel their tissue environment. Over the course of treatment, vessel density in ischemic
tissues increases in FGF1-laden tissue regions (within 500–600 μm depth from epicardium,
Fig 5b). Indeed, abundant neovascularization occurs from day 2 to 8, but drug washout rises
as well precipitously dropping the local tissue concentration of FGF1 (Fig 5a) and penetration
depth of FGF1, despite no quantifiable change in growth factor delivery. FGF1's instability in
the absence of heparin35 cannot account for the observed effects, as the factor was released
directly from the heparin Sepharose devices to the epicardial tissue. Released FGF1 likely
binds reversibly to myocardial HSPGs prolonging its tissue half-life. Indeed, angiogenic
activity was observed 8 days after delivery (Fig 5). Moreover, changes in angiogenic action
correlated with regression of FGF1 distribution, not a decrease in activity or stability.
Continuum pharmacokinetics (Eq. S15, Supplemental Methods) suggest a 5-fold increase in
capillary washout between days 2–8. Such an increase in the FGF1 clearance could arise from
an increase in microvascular density and/or trans-endothelial permeability (Eq. 2, Table 1).
The observed 65 % rise in capillary density between days 2 and 8 indicates that the latter plays
a dominant role and suggests that the induced vasculature is immature and highly permeable
to FGF1.
Our findings, therefore, offer possibilities for engineering drugs to penetrate tissue better by
reducing their trans-endothelial permeability. FGF2 lies within the region where drug
penetration depth is highly sensitive to the clearance rate constant k (Fig. 4a) which is directly
proportional to trans-endothelial permeability (Eq. 2, Table 1), whereas (FGF2)2-SOS with its
2.6 times lower clearance is less affected by flow. More than 50 % of FGF2 is cleared by
coronary perfusion, but only 12 % for (FGF2)2-SOS (Fig. 1 vs. Fig. 3b). Therefore, one way
to decrease permeability is to consider drugs of higher molecular weight. While higher
molecular weight implies lower myocardial drug diffusivity, the ratio of permeability to
diffusivity can drop two orders of magnitude as molecular radius increases from 2.4 to 36 Å
26. A different method for modulating trans-endothelial permeability is by modification of drug
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charge. Indeed, it has been shown that negatively charged dextrans exhibit 10 times lower
trans-endothelial permeability than neutral analogs36. This approach may present a method for
lowering trans-endothelial permeability of a drug to increase penetration depth and deposition.
Our study also highlights the impact of capillary clearance on myocardial drug distribution and
elimination, and sets a ceiling for the depth of drug penetration at steady state. Such clearance
is dependent on the trans-endothelial permeability of the delivered drug, and tissue vascularity.
At normal arterial pO2, a significant portion of capillaries is relatively constricted. Normal
myocardium can respond swiftly to arterial hypoxia through active hyperemia by dilating
capillaries and effectively decreasing intercapillary distance and thus oxygen diffusion
barrier37. Through reactive hyperemia the glycocalyx lining of endothelial cells can be
modified by reactive oxygen species to increase transendothelial permeability, and capillary
and postcapillary venule diameter38. However, myocardial capillary density declines markedly
with ischemia and infarction, limiting capillary reserve39–41. Because capillaries act as
spatially distributed sinks to drug, myocardium with denser functional vascularity will clear
drug more efficiently and rapidly, creating zones of low drug concentration. Gradation in
vascularity in diseased tissue thus has important consequences for local drug delivery. Since
capillary flow in ischemic and infarcted regions is substantially lower than in normal tissue,
our data predict that drug penetration would be greater. Placing delivery devices directly in the
ischemic region should confer the pharmacokinetic advantages of decreased capillary washout;
in well-perfused regions, drug molecules may never reach ischemic areas at sufficient levels.
Pericardial delivery of growth factors to target endocardial ischemic regions may thus prove
futile since drugs will not easily cross well-perfused epicardial regions. Indeed, drug
penetration in the presence of capillary perfusion was limited ex vivo (Fig. 1) and in vivo (Fig.
5) despite ample time for distant diffusion.
The integrated studies presented suggest that angiogenesis is powerfully self-regulating as the
very capillaries induced by angiogenic drug therapy may increase clearance as well. The
pharmacodynamic changes during the early angiogenic therapy can tip the pharmacokinetics
to conditions that are unfavorable for growth factor penetration, which in turn affects long term
therapeutic goals. This mechanism implies a natural upper limit effect for pharmacologic
revascularization which restricts angiogenic drug penetration and spatially confines the
sprouting of new vessels near the drug source. At day 31, the FGF1 level in the 100–500 μm
tissue region falls to undetectable levels, and significant regression of neovascularization
consequently occurs in the absence of local growth factor (Fig 5c). One might well imagine
that such forces are essential to endogenous regulation of tissue morphogenesis and repair, and
that loss of such regulation may help explain the growth of vascular tumors, and other arterial-
venous malformations and anomalies.
The interdependence of the pharmacokinetics and pharmacodynamics elucidated in this study
may explain the difficulty of realizing the clinical potential of angiogenic compounds and
suggests that efficacy becomes critically dependent on device placement and drug's trans-
endothelial permeability. The quantitative framework presented here may help guide rational
selection of angiogenic compounds based on a favorable physicochemical profile, and drug
delivery strategies that take advantage of the regulation between growth factor
pharmacokinetics and angiogenic pharmacodynamics.
Clinical summary
Pro-angiogenic growth factors have long been considered for regenerating ischemic tissues.
Yet, sustained clinical benefit has not followed promising preclinical findings even with
advances in local delivery technology. Quantitative and animal models suggest that the
limited late efficacy of local delivery of angiogenic factors stems partly from the very early
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success at inducing vessel growth. Fibroblast Growth Factor (FGF) released from a
polymeric implant penetrates ischemic rabbit myocardium in vivo for the first two days of
local delivery and indeed induces neovascularization. But as new vessels are formed drug
is cleared rapidly, and the induced vessel mass regresses. As each wave of new vessels
appears in response to the angiogenic factor pools, the factors are cleared and the angiogenic
signal abates as a receding wave that implodes back towards the growth factor source.
Despite a constantly eluting source of FGF, the front of new vessels continues to fall back.
Eight days after release initiation neovascularization remains but only as a regressed zone
immediately around the delivery device. By day 30 there is only a superficial layer of vessels
around the release device.
This interdependence of pharmacokinetics and pharmacodynamics may explain the
difficulty of realizing sustained clinical angiogenesis with local release and suggests that
efficacy depends on device placement and drug trans-endothelial permeability. The
quantitative framework presented here may help guide rational selection of specific
angiogenic compounds based on a favorable physicochemical profile, and drug delivery
strategies that take advantage of the tight regulation between growth factor
pharmacokinetics and angiogenic pharmacodynamics.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1. Myocardial Capillary perfusion Impedes Drug Penetration
Distribution and representative fluorescence microscopy images of TR-FGF2 in rat
myocardium with (magenta) and without coronary perfusion (blue). Data represent mean ±
s.e.m. (n=3). Penetration depth (x90) is estimated as the location of the 90 % drop-off from the
threshold (vertical dashed lines).
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FIGURE 2. Continuum Pharmacokinetic Model
Penetration depth x90,defined as distance from source to 90 % drop-off threshold, x90 = ℓ × ln
(10), where ℓ is calculated based on Eq. 4 (Table 1), is expressed as a function of drug diffusivity
(a), trans-endothelial permeability (b), and capillary volume fraction (c). Parameter values
cover a range of two orders of magnitude below to above those of FGF2 in the heart. FGF2
diffusivity = 0.02 μm2s−1 and clearance constants k were empirically verified, and trans-
endothelial permeability derived from Eq. 2 (Table 1). Capillary volume fraction (ϕmv) was
varied over 3 log orders between the extremes of ischemic and normal tissue vascularity25.
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These relationships are linear in log-log scale axes, demonstrating adherence to power law
functions.
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FIGURE 3. FGF Distribution is Sensitive to Alteration in Drug Clearance
(a) Percent drug cleared by capillaries calculated using the analytical model (Eq. 5, Table 1)
as a function of clearance rate constant k (black line). Experimental data points for TR-FGF2
and TR-(FGF2)2-SOS analyzed by Eq. M1 (Methods) are superimposed (magenta squares) on
model predictions providing perspective on the sensitivity of FGF2 to manipulation of its
clearance constant. (b) Distribution and representative fluorescence microscopy images of TR-
(FGF2)2-SOS in rat myocardium with coronary perfusion (magenta) and without coronary
perfusion (blue). Data represent mean ± s.e.m. (n=3).
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FIGURE 4. Polymeric Devices Sustain Release FGF1 over 30 days
(a) Cross sectional area of H&E stained rabbit myocardial tissue shows location of drug release
source (adjacent to left ventricular free wall) and interface between drug source and
myocardium. (b) Percentage of cumulative 35S-FGF1 released into PBS buffer in-vitro (white
diamonds, data represent mean ± s.e.m. (n=10), 100% corresponds to approximately
90μg 35S-FGF1 per circular disk of 8mm diameter and 1mm thickness), and throughout in-
vivo experiment (black circles, data represent mean ± s.e.m. (n=3), 100% corresponds to
approximately 450 μg 35S-FGF1 per device (20mm × 20mm × 1mm) for in-vivo experiments),
calculated by % drug released = (total drug within source – total drug remaining)/ total drug
within source × 100 %.
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FIGURE 5. In-vivo Ischemic Heart Model
(a) Spatial distributions of tissue S35-FGF1 concentration at days 2, 8, and 31 following
coronary ligation and implantation of sustained release source. FGF1 was quantified using
liquid scintillation counting following serial sectioning. Data represent mean ± s.e.m. (n=3)
(b) Representative fluorescent images of PECAM-1 labeled blood vessels in tissue regions
adjacent to drug source for experimental animals receiving heparin-Sepharose beads / alginate
source with S35-FGF1 and control animals receiving devices without FGF1. Dashed red line
on the right edge denotes interface between source and epicardium. Magenta, blue and green
dashed lines represent the penetration depth at 90 % drop-off threshold from tissue/source
interface calculated from spatial S35-FGF1 distributions. (c) Vascular to tissue surface fraction
(calculated by normalizing total number of pixels stained by PECAM-1 to total tissue area
within 500 μm depth from source) is expressed as a function of time. Scale bars represent 100
μm. Data points represent PECAM-1 stained surface fraction of individual hearts (n=3), and
connecting lines denote trend of mean value. * denotes P < 0.05. ** denotes P < 0.01 (P =
0.007 between days 2 and 8, and P = 0.003 between days 8 and 31).
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TABLE 1
Continuum Pharmacokinetic Model Equations for Epicardial Drug Delivery
Detailed derivations are included in Supplemental Methods. Eq. 1 describes the transport of drug in the presence of
capillary clearance. C represents drug concentration in the tissue as a function of time t, distance from the epicardium
x, diffusivity D and apparent clearance constant k. Eq. 2 relates the apparent clearance constant k to capillary
permeability Pmv, capillary volume fraction ϕmv and capillary diameter Rmv. Eq. 3 describes steady state tissue
concentration normalized to source concentration Co in the absence of capillary perfusion. Eq. 4 shows the steady state
tissue concentration in the presence of capillary perfusion, where ℓ is drug penetration depth. Eq. 5 shows the percent
drug clearance by capillary perfusion as a function of k and D.
Eq. 1
∂C
∂t − D
∂2C
∂ x 2
= − kC
Eq. 2 k = ( 2Rmv ) Pmvϕmv1 − ϕmv
Eq. 3 C ∕ C0 ≈ erfc( x2 Dt )
Eq. 4 C = C0e−x∕ℓ, ℓ = Dk
Eq. 5 % clearance = 100 × 1 − ℓerf( kt)4Dt ∕ π
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